Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire
dc.contributor.author | Chung, Lorinda | en_US |
dc.contributor.author | Chen, Hubert | en_US |
dc.contributor.author | Khanna, Dinesh | en_US |
dc.contributor.author | Steen, Virginia D. | en_US |
dc.date.accessioned | 2013-03-05T18:17:49Z | |
dc.date.available | 2014-05-01T14:28:12Z | en_US |
dc.date.issued | 2013-03 | en_US |
dc.identifier.citation | Chung, Lorinda; Chen, Hubert; Khanna, Dinesh; Steen, Virginia D. (2013). "Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire." Arthritis Care & Research 65(3): 454-463. <http://hdl.handle.net/2027.42/96723> | en_US |
dc.identifier.issn | 2151-464X | en_US |
dc.identifier.issn | 2151-4658 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/96723 | |
dc.description.abstract | Objective The University of California in San Diego Shortness of Breath Questionnaire (UCSD SOBQ) has been used to assess dyspnea‐related activity limitation in patients with airway and parenchymal lung disease. We sought to assess the construct validity and responsiveness of the UCSD SOBQ in systemic sclerosis (SSc; scleroderma) patients with incident pulmonary hypertension (PH) and those at high risk of developing PH. Methods We used data from 179 patients enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry with pre‐PH (defined by criteria on pulmonary function tests and/or echocardiogram) or definite PH with mean pulmonary artery pressure ≥25 mm Hg by right‐sided heart catheterization within 6 months of enrollment. For this analysis, we included those subjects with complete data for self‐reported measures at baseline and at 12 months. Results At baseline, the UCSD SOBQ had strong correlations in the expected direction with the disability index (DI) of the Health Assessment Questionnaire (HAQ) (r = 0.71, P < 0.0001), dyspnea assessment by visual analog scale (r = 0.71, P < 0.0001), and the Short Form 36 (SF‐36) health survey physical component summary (PCS) score (r = −0.77, P < 0.0001), as well as a moderate correlation with the 6‐minute walk test distance (r = −0.33, P < 0.0001), Borg dyspnea score (r = 0.47, P < 0.0001), and diffusing capacity of carbon monoxide (r = −0.33, P < 0.0001). Change in the UCSD SOBQ at 12 months correlated in the expected direction with change in the HAQ DI (r = 0.54, P < 0.0001) and change in the SF‐36 PCS (r = −0.44, P < 0.0001). Multivariate analysis adjusting for age, sex, and race identified male sex as a significant predictor of death (odds ratio [OR] 7.00, 95% confidence interval [95% CI] 1.55–31.76), while the UCSD SOBQ showed a strong trend toward significance (OR 1.82, 95% CI 0.97–3.41). Conclusions The UCSD SOBQ demonstrates good construct validity and responsiveness to change in SSc patients with pulmonary vascular disease. | en_US |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.title | Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationother | Stanford University and VA Palo Alto Health Care System, Palo Alto, California | en_US |
dc.contributor.affiliationother | 3801 Miranda Avenue, VA Palo Alto Health Care System, Palo Alto, CA 94305 | en_US |
dc.contributor.affiliationother | Georgetown University, Washington, DC | en_US |
dc.contributor.affiliationother | University of California, San Francisco, and Genentech, San Francisco, California | en_US |
dc.identifier.pmid | 23042670 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/96723/1/21827_ftp.pdf | |
dc.identifier.doi | 10.1002/acr.21827 | en_US |
dc.identifier.source | Arthritis Care & Research | en_US |
dc.identifier.citedreference | Sekhon S, Pope J, Baron M. The minimally important difference in clinical practice for patient‐centered outcomes including Health Assessment Questionnaire, fatigue, pain, sleep, global visual analog scale, and SF‐36 in scleroderma. J Rheumatol 2010; 37: 591 – 8. | en_US |
dc.identifier.citedreference | Kupferberg DH, Kaplan RM, Slymen DJ, Ries AL. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil 2005; 25: 370 – 7. | en_US |
dc.identifier.citedreference | Johnson SR, Hawker GA, Davis AM. The Health Assessment Questionnaire disability index and Scleroderma Health Assessment Questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Rheum 2005; 53: 256 – 62. | en_US |
dc.identifier.citedreference | Rannou F, Poiraudeau S, Berezne A, Baubet T, Le‐Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36‐Item Short Form Health Survey. Arthritis Rheum 2007; 57: 94 – 102. | en_US |
dc.identifier.citedreference | Ware JE, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care 1992; 30: 473 – 83. | en_US |
dc.identifier.citedreference | Gliddon AE, Dore CJ, Maddison PJ, and the Quins Trial Study Group. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006; 55: 473 – 9. | en_US |
dc.identifier.citedreference | Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al. Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592 – 600. | en_US |
dc.identifier.citedreference | Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF‐36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 832 – 40. | en_US |
dc.identifier.citedreference | Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al. Impact of oral cyclophosphamide on health‐related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis Rheum 2007; 56: 1676 – 84. | en_US |
dc.identifier.citedreference | Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988. | en_US |
dc.identifier.citedreference | Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009; 135: 137 – 42. | en_US |
dc.identifier.citedreference | Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D‐penicillamine study. Ann Rheum Dis 2006; 65: 1325 – 9. | en_US |
dc.identifier.citedreference | Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998; 25: 198 – 9. | en_US |
dc.identifier.citedreference | Bellamy N. Clinimetric concepts in outcome assessment: the OMERACT filter. J Rheumatol 1999; 26: 948 – 50. | en_US |
dc.identifier.citedreference | Baron M, Sutton E, Hudson M, Thombs B, Markland J, Pope J, et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 2008; 67: 644 – 50. | en_US |
dc.identifier.citedreference | Hinchcliff M, Beaumont JL, Thavarajah K, Varga J, Chung A, Podlusky S, et al. Validity of two new patient‐reported outcome measures in systemic sclerosis: Patient‐Reported Outcomes Measurement Information System 29‐item Health Profile and Functional Assessment of Chronic Illness Therapy–Dyspnea short form. Arthritis Care Res (Hoboken) 2011; 63: 1620 – 8. | en_US |
dc.identifier.citedreference | Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health‐related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford) 2007; 46: 296 – 301. | en_US |
dc.identifier.citedreference | Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005; 2: 105 – 10. | en_US |
dc.identifier.citedreference | Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581 – 6. | en_US |
dc.identifier.citedreference | Hissaria P, Lester S, Hakendorf P, Woodman R, Patterson K, Hill C, et al. Survival in scleroderma: results from the population‐based South Australian Register. Int Med J 2011; 41: 381 – 90. | en_US |
dc.identifier.citedreference | Fransen J, Popa‐Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5‐year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70: 1788 – 92. | en_US |
dc.identifier.citedreference | Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten‐Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma‐related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043 – 50. | en_US |
dc.identifier.citedreference | Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972‐2002. Ann Rheum Dis 2007; 66: 940 – 4. | en_US |
dc.identifier.citedreference | Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward‐Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community‐based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52: 2125 – 32. | en_US |
dc.identifier.citedreference | Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088 – 93. | en_US |
dc.identifier.citedreference | Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792 – 800. | en_US |
dc.identifier.citedreference | Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease‐associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383 – 94. | en_US |
dc.identifier.citedreference | Hinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38: 2172 – 9. | en_US |
dc.identifier.citedreference | Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290 – 8. | en_US |
dc.identifier.citedreference | Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N‐terminal brain natriuretic peptide (NT‐proBNP) in scleroderma‐associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485 – 94. | en_US |
dc.identifier.citedreference | Cavagna L, Caporali R, Klersy C, Ghio S, Albertini R, Scelsi L, et al. Comparison of brain natriuretic peptide (BNP) and NT‐proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37: 2064 – 70. | en_US |
dc.identifier.citedreference | Eakin EG, Sassi‐Dambron DE, Ries AL, Kaplan RM. Reliability and validity of dyspnea measures in patients with obstructive lung disease. Int Behav Med 1995; 2: 118 – 34. | en_US |
dc.identifier.citedreference | Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire, University of California, San Diego. Chest 1998; 113: 619 – 24. | en_US |
dc.identifier.citedreference | Ries AL. Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med 2006; Suppl 1: 12 – 20. | en_US |
dc.identifier.citedreference | Swigris JJ, Yorke J, Sprunger DB, Swearingen C, Pincus T, du Bois RM, et al. Assessing dyspnea and its impact on patients with connective tissue disease‐related interstitial lung disease. Respir Med 2010; 104: 1350 – 5. | en_US |
dc.identifier.citedreference | Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137 – 45. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.